Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.85 |
| ▸ | PGR | P06401 | 7/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.85 |
| ▸ | AR | P10275 | 6/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.85 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.66 |
| ▸ | MMP1 | P03956 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11600203 | 1.00 | NR3C1 (0.85) | NR3C1PGRCYP3A4ARHIF1A | |
| SCHEMBL11875376 | 1.00 | NR3C1 (0.85) | NR3C1PGRCYP3A4ARHIF1A | |
| SCHEMBL11125210 | 1.00 | NR3C1 (0.85) | NR3C1PGRCYP3A4ARHIF1A | |
| SCHEMBL3164036 | 1.00 | NR3C1 (0.85) | NR3C1PGRCYP3A4ARHIF1A | |
| SCHEMBL11125211 | 1.00 | NR3C1 (0.85) | NR3C1PGRCYP3A4ARHIF1A | |
| SCHEMBL11600201 | 1.00 | NR3C1 (0.85) | NR3C1PGRCYP3A4ARHIF1A | |
| SCHEMBL11748063 | 0.93 | NR3C1 (0.85) | NR3C1PGRCYP3A4ARHIF1A | |
| SCHEMBL11755727 | 0.92 | PGR (0.85) | NR3C1PGRCYP3A4ARHIF1A | |
| Diflorasone Diacetate SCHEMBL10599667 | 0.92 | HIF1A (1.00) | NR3C1PGRCYP3A4ARHIF1A | |
| Diflorasone Diacetate SCHEMBL11020199 | 0.92 | HIF1A (1.00) | NR3C1PGRCYP3A4ARHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 517 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924397-A | Preparation process and application of diflorasone acetate and derivatives thereof | 浙江孚诺医药股份有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-117304248-A | Corticosteroid drug impurity compound, preparation method and application thereof | 浙江孚诺医药股份有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-116098866-A | Glucocorticoid fat emulsion for treating arthralgia, preparation method and application thereof | 中南大学湘雅医院 | 2023-05-12 | — | — | CN | claimed |
| CN-116077465-A | Nanometer preparation for joint pain relief, and preparation method and application thereof | 中南大学湘雅医院 | 2023-05-09 | — | — | CN | claimed |
| CN-116077669-A | Glucocorticoid nano-lipid carrier for treating arthralgia, preparation method and application thereof | 中南大学湘雅医院 | 2023-05-09 | — | — | CN | claimed |
| CN-115887421-A | Compound glucocorticoid film spraying agent and preparation and application thereof | 上海市第一人民医院 | 2023-04-04 | — | — | CN | claimed |
| CN-113453670-A | Transforaminal delivery of steroids and macromolecules | 乔·斯图丁 | 2021-09-28 | — | — | CN | claimed |
| CN-112888452-A | Cyclosporin compositions and methods of use | 贝凯恩生物医疗技术有限公司 | 2021-06-01 | — | — | CN | claimed |
| CN-107613985-B | Aqueous suspensions of nanoparticles containing glucocorticoids | 株式会社活效制药 | 2021-05-25 | — | — | CN | claimed |
| CN-111629716-A | Methods and compositions for treating inflammation | 马萨诸塞大学 | 2020-09-04 | — | — | CN | claimed |
| US-20120129824-A1 | Pharmaceutical Formulations Containing Corticosteroids for Topical Administration | JPMORGAN CHASE BANK, N.A. | 2012-05-24 | — | — | US | claimed |
| US-20090181933-A1 | USE OF STEROIDS TO TREAT PERSONS SUFFERING FROM OCULAR DISORDERS | ALCON, INC. (CH) | 2009-07-16 | — | — | US | claimed |
| US-20090012051-A1 | EXTERNAL PREPARATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-01-08 | — | — | US | claimed |
| EP-1916976-A2 | CONTROL OF INDUCED ELEVATED INTRAOCULAR PRESSURE | pSivida Inc (US) | 2008-05-07 | — | — | EP | claimed |
| US-20070287689-A1 | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-12-13 | — | — | US | claimed |
| EP-1810692-A1 | REMEDIES/PREVENTIVES FOR CHRONIC SKIN DISEASE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-25 | — | — | EP | claimed |
| WO-2007025275-A2 | CONTROL OF INDUCED ELEVATED INTRAOCULAR PRESSURE | PSIVIDA INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-20070049568-A1 | Control of induced elevated intraocular pressure | PSIVIDA INC. (US) | 2007-03-01 | — | — | US | claimed |
| US-20060154910-A1 | Use of steroids to treat ocular disorders | ALCON, INC. (CH) | 2006-07-13 | — | — | US | claimed |
| US-5236906-A | Adrenocortical hormone and hyaluronic acid; skin diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-08-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012051-A1 | EXTERNAL PREPARATION | CYP4A11, CYP46A1, CYP11B2 | NR3C1 556/4885PGR 2297/4885CYP3A4 91/4885 |
| US-20070287689-A1 | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | PDE4A, PDE3B, PDE2A | NR3C1 62/4885PGR 1575/4885CYP3A4 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.